EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 2013;127:e6–245.

2. Brown N, Melville M, Gray D, et al. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart 1999;81:352–8.

3. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 2002;87:140–5.

4. Arnold SV, Morrow DA, Lei Y, et al. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009;2:344–3.

5. Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) study. Arch Intern Med 2009;169:1491–9.

6. Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch Intern Med 2008;168:1310–6.

7. Duarte R, Castela S, Reis RP, et al. Acute coronary syndrome in a diabetic population—risk factors and clinical and angiographic characteristics. Rev Port Cardiol 2003;22:1077–88.

8. Herlitz J, Wognsen GB, Emanuelsson H, et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 1996;19:698–703.

9. Peterson PN, Spertus JA, Magid DJ, et al. The impact of diabetes on one-year health status outcomes following acute coronary syndromes. BMC Cardiovasc Disord 2006;6:41.

10. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032–9.

11. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904–10.

12. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375–82.

13. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311–6.

14. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–16.

15. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–75.

16. Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010;33: 1163–8.

17. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42–8.

18. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.

19. Guy W. ECDEU Assessment Manual for Psychopharmacology (DHEW Publication No. ADM 76–338). Washington, DC: U.S. Government Printing Office, 1976.

20. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.

21. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007;298:765–75.

22. Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993;22:1433–7.

23. Murray DP, O’Brien T, Mulrooney R, O’Sullivan DJ. Autonomic dysfunction and silent myocardial ischaemia on exercise testing in diabetes mellitus. Diabet Med 1990;7:580–4.

24. Chiariello M, Indolfi C, Cotecchia MR, Sifola C, Romano M, Condorelli M. Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients. Am Heart J 1985;110:529–34.

25. Nishio S, Teshima Y, Takahashi N, et al. Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart. J Mol Cell Cardiol 2012;52:1103–11.

26. Koval OM, Snyder JS, Wolf RM, et al. Ca2+/calmodulin-dependent protein kinase II-based regulation of voltage-gated Na+ channel in cardiac disease. Circulation 2012;126:2084–94.

27. Yao L, Fan P, Jiang Z, et al. Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventric- ular myocytes and N1325S mice. Am J Physiol Cell Physiol 2011;301:C577–86.

28. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117:1610–9.

29. Jackson G, Schwartz J, Kates RE, Winchester M, Harrison DC. Atenolol: once-daily cardioselective beta blockade for angina pectoris. Circulation 1980;61:555–60.

30. Weiss R, Ferry D, Pickering E, et al. Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. Am J Cardiol 1998;82:927–31.

31. Estrada JN, Saglietti H, Di Marco M, Casabe H, Oliveri R. Antiischemic properties of amlodipine, a new calcium antagonist, in patients with severe coronary artery disease: a prospective trial. Am Heart J 1989;118:1130–2.

32. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chron- ic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540–8.

33. Frishman WH, Heiman M. Usefulness of oral nisoldipine for stable angina pectoris. The Nisoldipine Multicenter Angina Study Group. Am J Cardiol 1991;68:1004–9.

34. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ 2002;324:1193–4.

35. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 2008;1:107–15.